Impact of lesion volume on glibenclamide efficacy in large hemispheric infarction

W. Taylor Kimberly, MD, PhD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, discusses a post-hoc analysis of the CHARM study, focusing on the impact of baseline lesion volume. The Phase III CHARM study randomized patients with large hemispheric infarction to intravenous glibenclamide or placebo. Overall, while the drug was shown to be safe, there was no difference in functional outcomes at three months between the two groups. An exploratory analysis revealed that the drug improved outcomes at 90 days in patients with a lesion volume of around 120 mL or less, compared to a placebo. However, the drug's efficacy diminished in patients with larger stroke volumes. This interview took place at the 10th European Stroke Organisation Conference (ESOC) 2024 in Basel, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.